GFM
BEAM icon

GF Fund Management’s Beam Therapeutics BEAM Stock Holding History

GF Fund Management’s Portfolio BEAM Stock Details BEAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$54.3K Buy
2,279
+285
+14% +$7.91K ﹤0.01% 388
2025
Q4 		$55.3K Sell
1,994
-182
-8% -$4.64K ﹤0.01% 399
2025
Q3 		$52.8K Buy
2,176
+56
+3% +$1.11K ﹤0.01% 390
2025
Q2 		$36.1K Hold
2,120
– – ﹤0.01% 447
2025
Q1 		$41.4K Buy
2,120
+381
+22% +$9.98K ﹤0.01% 439
2024
Q4 		$43.1K Buy
+1,739
New +$44.4K ﹤0.01% 401

Other funds holding BEAM

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

GF Fund Management's BEAM Position: Q1 2026 in Review

GF Fund Management increased its Beam Therapeutics (BEAM) stake by 14% in Q1 2026, buying an estimated $7.91K and bringing the position to 2,279 shares worth $54.3K. The position accounts for ﹤0.01% of the portfolio, ranked #388.

GF Fund Management first reported a position in BEAM in Q4 2024 and has held it in 6 quarters since. The position peaked at $55.3K in Q4 2025. 251 funds tracked by Wall St. Rank hold BEAM as of Q1 2026.

  • GF Fund Management held 2,279 shares of Beam Therapeutics worth $54.3K as of Q1 2026.
  • GF Fund Management bought 285 Beam Therapeutics shares in Q1 2026, an estimated $7.91K.
  • Beam Therapeutics made up ﹤0.01% of GF Fund Management's portfolio in Q1 2026, its #388 holding.
  • GF Fund Management first reported a position in Beam Therapeutics in Q4 2024 and has held it in 6 quarters since.
  • GF Fund Management's Beam Therapeutics position peaked at $55.3K in Q4 2025.
  • 251 funds tracked by Wall St. Rank held Beam Therapeutics as of Q1 2026.

Based on GF Fund Management's 13F filing for Q1 2026, filed 15 Apr 2026.